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Abstract Recent reports reveal that the C-terminal half of the 
neuroendocrine polypeptide 7B2 selectively inhibits and binds 
PC2, a mammalian prohormone converting enzyme that is homol- 
ogous to the yeast pro-a-factor processing protease Kex2. During 
attempted secretion of the 185 amino-acid human 7B2 in Sac- 
charomyces cerevisiae, we observe that the protein is mostly 
retained inside the cell. However a mutant polypeptide (7B2A1), 
where the C-terminal 48 amino acids of 7B2 are deleted, is effi- 
ciently secreted. Two shorter C-terminal truncations either per- 
mit poor secretion or no secretion at all. Surprisingly, full-length 
7B2 but not 7B2AI abolishes the catalytic activity of Kex2, 
indicating that C-terminal residues of 7B2 might also be impor- 
tant for inhibition of the yeast protease. When the KEX2 gene 
is disrupted, yeast cells unexpectedly secrete a 7B2 variant simi- 
lar in size to 7B2A1, suggesting involvement of the alternate yeast 
prohormone convertase Yap3 in processing. Secretion is en- 
hanced by overexpression of Yap3 and by the presence of a 
Lys-Arg residue at the processing site of precursor 7B2. These 
results purport that, in neuroendocrine cells too, secretion of 7B2 
could be mediated by a homologue of Yap3. 
Key words: 7B2; Kex2 inhibition; PC2 convertase; Processing 
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I. Introduction 
The 7B2 protein is present selectively in the regulated secre- 
tory pathway of neurons and endocrine cells [1-2]. It is pro- 
duced in all hormone-synthesizing cells of the pituitary gland 
and is distributed widely in different regions of the brain [2]. 
Within the cell, 7B2 is stored in the secretory granules uggest- 
ing that it may partake in the secretion of peptide hormones, 
Release of hormones from the cell is triggered by specific exter- 
nal stimulii, events typical of secretion in the regulated secre- 
tory pathway. Before actual secretion, prohormones are first 
converted to active hormones by specialized enzymes known as 
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Abbreviations." 7B2, the neuroendocrine protein 7B2; human 7B2, full- 
length 7B2 (1-185 amino acids), excluding the signal peptide; 7B2A1, 
human 7B2(1-137); 7B2zJ2, human 7B2(1-149); 7B2A3, human 7B2 
(I-170); 7B2ss, signal sequence of the human 7B2 gene; CYPlp, the 
promoter of the S. cerevisiae cytoplasmic cyclophilin gene; ER, endo- 
plasmic reticulum; GAPDHp, the promoter of the S. cerevisiae glyceral- 
dehyde-3-phosphate dehydrogenase gene; IGF1, human insulin-like 
growth factor-l; Invss, the yeast SUC2 signal sequence; PCR, polym- 
erase chain reaction; PHO5t, transcription terminator of the yeast 
PH05 gene; POMC, proopiomelanocortin. 
the prohormone convertases [3]. It appears that 7B2 itself be- 
haves like a prohormone and is often exported into the extracel- 
lular medium after due processing [4]. 
All the known 7B2 cDNA sequences from different species 
encode signal peptides [5] which normally allow entry of nas- 
cent proteins into the secretory pathway. Comparison of the 
various mature polypeptides reveals that 7B2 is a highly con- 
served protein. Although its physiological importance has long 
been suspected, it was only recently that 7B2 was found to play 
a major role in preventing premature activation of the precur- 
sor form of the prohormone convertase PC2 [6]. In vitro exper- 
iments suggest hat the C-terminal halt" of 7B2 may be an en- 
dogenous inhibitor of mature PC2 [7]. 
Besides the overall similarity, the amino-acid sequences of 
7B2 from different species exhibit conservation i a set of basic 
residues, Arg-Xaa-Lys/Arg-Arg (at position 148/149 of the pol- 
ypeptide sequences). Although this motif is generally not used 
as a substrate for processing in the regulated secretory path- 
way, mammalian 7B2 proteins are cleaved at this site. Cleavage 
is concomitant with secretion of a 21-kDa truncated molecule 
[8 9]. However, processing in the intermediate lobe of the Xen- 
opus laevis (the South African clawed toad) pituitary glands, 
where 7B2 is co-expressed with the prohormone proopiomela- 
nocortin (POMC), is different [5]. It occurs at a LysI38-Lys 139 
pair of basic residues, which is N-terminal to the Arg-Xaa-Lys/ 
Arg-Arg motif, and leads to the secretion of a 18-kDa deriva- 
tive of 7B2 [5]. Although the variations in processing are inex- 
plicable, the available data makes it abundantly clear that full- 
length 7B2 is never secreted in mammals or in the Xenopus. 
In contrast o the complexities of the regulated secretory 
pathway of neuroendocrine c lls, the yeast Saccharomyces cer- 
evisiae offers a simple model system in which processing and 
secretion of 7B2 could be studied in the constitutive secretory 
pathway. In yeast, two unique prohormone convertases have 
been unambiguously identified: (i) Kex2, a member of the sub- 
tilisin family of serine proteases, functionally and structurally 
related to its mammalian counterparts PC1/PC3 and PC2 [9] 
and (ii) Yap3, an aspartic protease, a putative homologue of 
the POMC converting enzyme [10]. The YAP3 gene product 
has the ability to suppress the phenotype of a kex2 null mutant 
[11]. 
We have inquired if the complete human 7B2 polypeptide 
would be secreted in yeast when allowed entry into its secretory 
pathway. It appears that, in this unicellular eukaryote too, a 
C-terminal domain of 7B2 needs to be cleaved for secretion to 
occur. The enzyme which accomplishes this cleavage is not 
Kex2 but another endoprotease which, in all likelihood, is 
Yap3. The C-terminal domain of 7B2 appears to be instrumen- 
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tal in the inhibit ion of Kex2 but not of the alternate nzyme. 
These observations not only unveil similarities in the biochem- 
ical conversion of precursor 7B2 in organisms which are quite 
distantly related in evolution, but also hint that an enzyme 
resembling Yap3/POMC convertase may be responsible for 
processing 7B2 in neuroendocrine c lls. 
2. Materials and methods 
2.1. DNA constructions of human 7B2, linked to signal sequences from 
human 7B2 and yeast SUC2 genes, for secretion in yeast 
An EcoRI Sphl fragment of the 7B2 coding sequence, linked at the 
N-terminus to a 54 bp human 7B2 signal sequence (7B2ss; see Fig. 1), 
was amplified by the polymerase chain reaction (PCR) [12] using 
human 7B2 cDNA as template (kindly provided by Dr. G.J.M. Mar- 
tens, University of Nijmegen, The Netherlands) [13]. The primers used 
were 
5'-ATGAATTCATGCTATCTGGCCTACTG-3' 
and 
5'-TAGCATGCTTACTCTGGATCCTTATC- 3' 
The last two amino-acid residues encoded by the PCR fragment are 
Pro ~s4 and Glu t~5 and are followed by a stop codon. The EeoRl SphI 
fragment was subcloned in pBluescriptKS+ (Stratagene) and the result- 
ing plasmid was named pBluelEcoRI SphlI7B2ss-7B2. 
A fusion between the S. cerevisiae sue2  signal sequence (Invss) [14] 
and the human 7B2 gene [13] was created as follows (see Fig. 1). A ~465 
bp BamHI XhoI (5' to 3') fragment from pUC19IBamHI XhoI! 
GAPDH-Invss, containing the 400 bp promoter region of the S. eerevis- 
iae glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene [15] 
and 57 bp of the chemically synthesized Invss (the promoter and Invss 
are linked by an EcoRI site), was flushed at the T-end and ligated to 
Ncol linkers. Similarly, a ~270 bp EcoRI-Sael fragment from the 5'-end 
of the human 7B2 cDNA (see Fig. 1; the EcoRl site of which is flushed 
and converted to NcoI by linker ligation), was isolated. The resulting 
BamHl NcoI and the NcoI Sacl fragments were subcloned in pUCI9 
yielding the template (pUC 19/GAPDHp-Invss-7B2) for PCR-mediated 
deletion mutagenesis. The three primers used for the construction ofan 
exact fusion between the Invss and 7B2 DNA sequences were: 
5"-GCAGCCAAAATATCTGCATACAGCCCCCGGACCCCT-3' 
(spans the 3'-end of the coding strand of lnvss and 5'-end of the 7B2) 
5'-ATGAGCTCCACCTTCAATGC-3' (spans the SacI site of 7B2 and 
belongs to the non-coding strand of the 7B2 gene) 
and 
5'-TAGAATTCATGCTTTTGCAAG-3' (spans the EcoR1 site and the 
5'-end of the coding sequence of Invss) 
The ~ 220 bp EcoR1-SacI product of the PCR reactions, encompassing 
the complete Invss and the DNA encoding the first 52 amino-acid 
residues of 7B2 (see Fig. 1), was confirmed by DNA sequencing. This 
EeoRI-Sacl segment of DNA and the ~400 bp SacI-SphI fragment from 
pBlue/EcoRI-SphI/7B2ss-7B2 were subcloned in pBluescriptKS+ to 
yield the plasmid pBlue/EcoRI-Sphlllnvss-7B2 (1-185). 
2.2. DNA construction of the 7B2 variants 7B2A1, 7B2A2 and 7B2A3 
fused to Invss 
The genes for 7B2AI, 7B2A2 and 7B2A3 (see Fig. 1), already fused 
to 7B2ss, were obtained by deleting 3'-end regions from the wild type 
human 7B2 gene [13]. The three mutant genes (either as EcoRI-SphI 
or as EcoRI HindIII fragments) encode the N-terminal 137, 149 and 
170 amino acids of human 7B2. The primers used for constructing the 
deletions are depicted in Table 1. The authenticity of the gene con- 
structs was confirmed by sequencing. 
The EcoRI-SucI segment, containing Invss fused to an N-terminal 
part of 7B2 (see Fig. 1), and a SacI-SphI fragment from the 7B2A1 gene 
were subcloned in pBluescriptKS+ to obtain pBlue/EeoRI SphI/Invss- 
7B2AI. The plasmids pBlue/EcoRI HindIII/Invss-7B2A2 and pBlue/ 
EcoRI HindIII/Invss-7B2A3 were obtained similarly (see Fig. 1), 
2.3. Construction of yeast 211-plasmids that encode cassettes for 
expression of7B2, 7B2A1, 7B2A2, 7B2A3, and for co-expression f
7B2/IGF1, 7B2AI/IGFI, 7B2/Yap3 
The ~ 545 bp BamHI EcoRI promoter fragment from the yeast cyto- 
plasmic cyclophilin gene (CYP1) [16] was isolated by PCR, using 
genomic DNA from the yeast strain $288C as template and the two 
primers 
5'-ATATGGATCCTCTAGAACCTTTCATCATCT-3', 
and 
5'-TAATGAATTCGGTAGTATTAGCGGTTGAGT-3' 
The BamHI EcoR1 CYP1 promoter (CYPlp), the EeoRI-SphI or 
EeoRI-HindIII signal sequence-7B2 fusions (obtained from plasmids 
which encode 7B2ss-7B2, Invss-7B2, Invss-7B2A1, Invss-7B2A2 or 
Invss-7B233) and a SphI-SalI or HindIII-SalI transcription terminator 
fragment from the yeast PH05 gene (PHO5t) [15] were subcloned in 
the 2/~-plasmid pDP34 (at its BamHI and SalI sites) to yield the plas- 
mids listed in Table 2. The vector pDP34 encodes the complete yeast 
2p sequence and the yeast selection marker URA3 [15]. 
For construction ofplasmids for co-expression f two genes of inter- 
est, a linker containing SacI, XhoI and Bglll sites were first introduced 
in the the unique SacI site of pDP34 [15] to yield the vector pDP34Xho. 
After subcloning the Invss-7B2 and Invss-7B2A1 genes (under the con- 
trol of CYPlp) in the BamHI, SaII sites of pDP34Xho, an Xhol frag- 
ment of the IGF1 expression cassette (under the control of GAPDHp) 
is ligated to the unique Xhol site of the vector. The resulting plasmids, 
pHB15 and pHBI6, are listed in Table 2. 
A BamHI Sacl YAP3 [11] expression cassette was assembled from 
a BamHI XbaI fragment which contains the promoter and the coding 
sequence of YAP3 and a XbaI-SacI YAP3 transcription terminator 
fragment. The fragments were obtained by PCR using genomic DNA 
from the strain $288C as template, American Type Culture Collection 
#26108, and the pairs of primers: 
5'-ATGGATCCCCGTTTTCTTTTCGTAAAAA-3', 
5'-ATTCTAGAATGTGGTAGGTAATATTATA-3' 
H ind l I I  
BamHI  EcoRI SacI  137 149 170 SphI  Sal I  
' ' '  i KK , ,,3' 5 _' ................ ; ;  .... ; : '  :KKIRRKRR 
I I I I I I I I I 
coding sequence terminator 
promoter ql 7B2 185) 
ql 7B2 A 11--~ 
1 149  
q 7B2 ~ 2 
1 170 
q 7B2~,3 
Fig. 1. The cassette used for expressing human 7B2 protein and its variants. All constructions are under the control of the constitutive CYP1 promoter 
[16], the transcription terminator being PHO5t, and have been subcloned as BamHI SalI fragments in the 2,u-vector pDP34 [15]. The restriction sites 
used for constructing the different expression cassettes are shown. 'ss' stands for either of the two signal sequences, Invss or the 7B2ss. The three 
motifs (KK, RRKRR and KK), containing basic amino acid residues, are putative processing sites for precursor 7B2 (see section 3). The lengths of 
wild type and mutant 7B2 polypeptides are also indicated. 
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Table 1 
Primers used for the construction of 7B2 variants fused to 7B2ss 
93 
Gene Fragment Primers used 
7B2ss-7B2AI EcoRI-SphI 
7B2ss- 7B2A2 EcoRI-HindlII 
7B2ss-7B2A3 EcoRl HindlIl 
(i) 5 ' -ATGAATTCATGCTATCTGGCCTACTG-3 '  
(ii) 5 ' -TAGCATGCTTAGTTCCACTTGCCCAAGCC-3 '  
(i) 5 ' -ATGAATTCATGCTATCTGGCCTACTG-3 '  
(ii) 5 ' -ATAAGCTTTTACTCTCCTCCCTTCATCTT-3 '  
(i) 5 ' -ATGAATTCATGCTATCTGGCCTACTG-3 '  
(ii) 5 ' -ATAAGCTTTTATGCAACAACATTATCCAG-3 '  
and 
5'-ATTCTAGAATGAAACTGAAAACTGTAAG-3', 
5'-ATGAGCTCTTATTAGAATATTAAAGCCT- 3'. 
The expression cassettes for YAP3 and Invss-7B2 were subcloned in 
pDP34Xho to yield the plasmid pHBI7 (see Table 2). 
2.4. Introduction of a Lys139Arg mutation in 7B2 by PCR-mediated 
site-directed mutagenesis followed by construction of 21t-plasmids 
.for expression of 7B2_K139R and co-expression of 7B2_K139Rl 
sKex2pHDEL 
In order to replace Arg '39 in human 7B2 by Lys, PCR-mediated 
site-directed mutagenesis was performed using the plasmid pHB5 (en- 
coding the Invss-7B2 gene) as template and the three primers, 5'- 
AAGTGGAACAAGAgACTCCTTTACGAG-Y (the lower case letter 
indicating the site where the Arg codon is changed), 5'-TAG- 
CATGCTTACTCTGGATCCTTATC-Y (the Y-end non-coding 
strand of 7B2 containing a SphI site) and 5'-TAGAATT- 
CATGCTTTTGCAAG-3' (the 5'-end coding strand of Invss contain- 
ing an EcoRI site). The mutation in the EcoRI-Sphl DNA fragment 
was confirmed by DNA sequencing. The fragments containing the 
CYPIp (BamHI-EcoRI), the Invss-7B2_K139R (EcoRI SphI) and the 
PHO5t (SphI-Sall) were subcloned in pDP34 [15] and the resulting 
plasmid is referred to as pHB13. To obtain a vector which would 
co-express Invss-7B2_K139R and sKex2pHDEL [18], the expression 
cassette of the latter was ligated to the unique XhoI site of pDP34Xho 
which already contained the lnvss-7B2_K139R gene in its BamHI-SalI 
sites. The resulting plasmid is known as pHB14 (see Table 2). 
2.5. Recombinant DNA techniques 
Yeast transformations [19] (see Table 2) were performed in S. eerevis- 
iae strains AB110 (Matot his4-580 leu2 ura3-52 pep4-3 [cir°]) [17] and 
AB1 lOkex2 (Mata his4-580 kex2::LEU2 ura3-52 pep4-3 [cir°]) [18]. 
Manipulation of DNA was carried out by using standard procedures 
[19]. Escherichia coil H B101 was used for the construction and propaga- 
tion of plasmids. PCR was performed using Pfu (Stratagene) DNA 
polymerase. All newly constructed DNA was sequenced by the dide- 
oxynucleotide chain-termination method, using the Applied Bio-Sys- 
terns 370A automated DNA sequencer. 
2.6. Expression of 7B2 and immunoblot analysis 
Proteins were expressed in YPD (1% bacto-yeast extract (Difco), 2% 
bacto-peptone (Difco), 2% glucose and 0.05% bovine serum albumin 
(Sigma Cat. No. A-7638); pH6.5). 
100 A600 cells (from 48 h cultures) were centrifuged and the superna- 
tants were separated from the cell pellets. 2 ml supernatants were 
concentrated 5-20-fold using Centricon-3 mini-concentrators (Ami- 
con). For PAGE analysis, 0.5 vol sample buffer (6% SDS, 0.15 M Tris, 
pH 6.8, 6raM EDTA, 30% glycerol, 0.05% Bromophenol blue) was 
added to the concentrated cell supernatants. The cell pellets were me- 
chanically lysed using 0.2 g glassbeads (0.3 mm diameter) and 200 BI 
sample buffer. When cellular proteins were required for endoglycosi- 
dase F (Boehringer) treatment, cells were lysed in 200/.tl 0.1 M sodium 
phosphate (pH 7) [18]. 
Immunoblot analyses of cell supernatants and lysates were per- 
formed according to previously published protocols [17]. The monoclo- 
nal 7B2 anti-serum MON-102 is specific for the residues 128-135 and 
was a gift from Dr. W.J.M. van de Ven of the University of Leuven, 
Belgium [20]. Rabbit polyclonal anti-serum was generated using puri- 
fied monomeric IGF1 [17]. 
3. Results and discussion 
In order to explore if human 7B2 would secrete from yeast, 
two signal sequences (the heterologous human 7B2ss and the 
homologous yeast Invss) [13-14] have been used. Signal pep- 
tides usually allow the first step in secretion, that is, permit 
translocation of nascent proteins across the membrane of the 
endoplasmic reticulum (ER). The constructions 7B2ss-7B2 
Table 2 
Plasmids and corresponding strains used for expression of 
and absence of Kex2 protease ~ 
7B2, and co-expression of 7B2/IGFI, 7B2/sKex2pHDEL and 7B2/Yap3 in the presence 
Plasmid name Encodes the gene(s) for Parent plasmid Yeast strain(s) used for Corresponding 
transformation yeast strain(s) 
pHB-C pDP34 AB 110 yHB-C 
pHB 1 7B2ss-7B2 pDP34 AB 110 yHB 1 
pHB5 Invss-7B2 pDP34 AB110 & AB 1 lOkex2 yHB5a & yHB5b 
pHB6 Invss-7B2A1 pDP34 AB110 & AB1 lOkex2 yHB6a & yHB6b 
pHB7 Invss-7B2A2 pDP34 AB 110 yHB7 
pHB8 Invss-7B2A3 pDP34 AB 110 yHB8 
pHBI3 Invss-7B2_K139R pDP34 AB110 & AB1 lOkex2 yHB13a & yhHBl3b 
pHB 14 lnvss-7B2_K 139R & pDP34Xho AB 110kex2 yHB 14 
sKex2pHDEL 
pHB15 Invss-7B2 & aFL-IGF1 pDP34Xho AB110 yHB15 
pHB16 Invss-7B2A1 & ~FL-IGF1 pDP34Xho AB110 yHBI6 
pHB17 Invss-7B2 & Yap3 pDP34Xho ABII0 & ABllOkex2 yHBl7a & yHBl7b 
pBC1 aFL-IGFI pDP34 AB110 & AB1 lOkex2 yBCla & yBClb 
"The promoters used for the expression of 7B2, IGFI [17], sKex2pHDEL [18] and Yap3 [11] are CYP1 [16], GAPDHp [15], KEX2p [21] and YAP3 
[11], respectively. 
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Fig. 2. Western blot analysis of intracellular nd secreted 7B2-1ike proteins expressed in yeast from plasmids described inTable 2. Cell supernatants 
and lysates, from different transformants were analyzed by 15% SDS-PAGE. Fractionated proteins were blotted to Immobilon-P membranes 
(Millipore) on a Sartorius emi-dry blotter and were detected using the 7B2 anti-serum MON-102 [20]. (A) Full-length uman 7B2 (a 185 amino-acid 
protein) does not secrete from yeast. (I) 10/tl supernatant from each culture (concentrated 20-fold; see section 2) was used. Lanes 1 and 2, yHB-C 
(negative control, bearing pDP34 with no expression cassette); lanes 3 and 4, yHB1 (7B2ss-7B2); lanes 5 and 6, yHB5a (Invss-7B2); lanes 7 and 8, 
yHB6a (Invss-7B2A1). (II) same as in (I) but for the use of 4/A cell lysate in each lane. (B) 7B2 and 7B2A3 does not secrete from yeast, whereas 7B2A1 
secretes better than 7B2A2. (I) Analysis of 10 ,ul supernatants (lanes 3-9). All samples were concentrated 20-fold except the supernatants from yHB6a 
which were concentrated only 5-fold. Lanes 1 and 2 have been used as controls. Lane 1,200 ng recombinant 7B2 protein, expressed in E. coli (kindly 
provided by G. Martens, University of Nijmegen and used as positive control; the upper band resembles the full-length protein whereas the lower 
band probably is a degradation product obtained uring purification); lane 2, yHB5a (Invss-7B2; 4/11 cell lysate; the 7B2-1ike protein in the cell lysate 
has a larger molecular mass than E. coli-produced 7B2, either because the Invss has remained partially uncleaved orthat 7B2 in yeast has undergone 
a type of post-translational modification which is not possible in E. coli); lane 3, yHB5a (Invss-7B2); lanes 4 and 5, yHB8 (Invss-7B2A3); lanes 6 
and 7, yHB7 (Invss-7B2A2); lanes 8 and 9, yHB6a (Invss-7B2A1). (II) 4/A cell lysate has been used in each lane. Lane 1,200 ng recombinant 7B2 
protein; lanes 2 and 3, yHB5a; lanes 4 and 5, yHB8; lanes 6 and 7, yHB7; lanes 8 and 9, yHB6a. Prestained low-molecular mass tandard proteins 
(Bio-Rad) were used as markers. 
(i.e. 7B2ss fused to human 7B2 gene) and Invss-7B2 (i.e. Invss 
fused to human 7B2 gene) are expressed under the control of 
the yeast CYPlp, a promoter element of the yeast cytoplasmic 
cyclophilin gene [16]. CYPlp promotes constitutive expression 
of heterologous proteins in a complex medium containing glu- 
cose as a carbon source (unpublished observations). The 
CYPlp is relatively weaker than the GAPDHp, known to be 
one of the strongest constitutive promoter in yeast [15]. The 
choice of the C YP1 promoter was guided by our initial inability 
to express 7B2 from the promoter of the yeast GAPDH gene 
(unpublished observations). 
Western blot examination of intracellular proteins from the 
yeast strains (see Table 2) yHB1 (harbouring 7B2ss-7B2) and 
yHB5a (harbouring Invss-7B2), using the 7B2-specific mono- 
clonal antibody MON-102 [20], reveals that 7B2-1ike proteins 
are indeed expressed in yeast (Fig. 2A-II). However, there was 
no convincing evidence to indicate that 7B2 truly secretes (Fig. 
2A-I). Even after 20-fold concentration of cell supernatants 
there was only a hint, barely visible on the immune-blot, that 
the strains yHB1 and yHB5a may have a propensity to secrete 
molecules which are smaller than full-length 7B2 (Fig. 2A-I, 
lanes 3-6). 
7B2 is secreted from mammalian and X. laevis neuroendo- 
crine cells only after the proteins have undergone processing at 
the C-terminal end of the molecule [5,8 9]. Since the full-length 
185 amino-acid human 7B2 is incapable of being secreted from 
yeast, it could be that removal of a region from the C-terminus 
of the protein is necessary for secretion to occur in S. cerevisiae. 
In fact, the very small amounts of 7B2-1ike molecules that are 
obtained from yHB1 and yHB5a (Fig. 2A-I, lanes 3 6) are 
similar in size to the proteins expressed by the mutant 7B2AI 
(Fig. 2A-I, lanes 7 and 8). The 7B2A1 gene should encode a 137 
amino-acid polypeptide yet it appears that 7B2A1 is expressed 
as a mixture of at least wo proteins, The polypeptide r present- 
ing the lower band is probably a proteolytic product of the 
upper band. Since both proteins are recognized by the mono- 
clonal antibody MON-102, specific for amino acids 128-135 of 
human 7B2 [20], it is probable that the upper band (represent- 
ing the true C-terminal truncation 7B2A1) has undergone inad- 
vertent N-terminal proteolysis. 
In order to delineate the C-terminal domain which inherently 
prevents ecretion of 7B2 in yeast, two more mutants were 
constructed (see Fig. 1). It was envisaged that smaller deletions, 
involving truncations at the 3'-end of the 7B2 gene and which 
remove 36 and 15 amino acids from the C-terminus of 7B2, 
would help to define this region. There are three sites in 7B2 
which contain pairs of basic residues (in the human protein they 
are Lys138-Lys lag, ArglS°-Arg-Lys-Arg-Arg 154, and Lys IvL 
Lysm), any one of which could be a putative processing site for 
a secreted prohormone-like protein [5,8-9]. We observe that the 
170 amino-acid 7B2A3 protein fails to secrete from yeast (Fig. 
2B, lanes 4 and 5), whereas the 149 amino-acid 7B2A2 secretes 
poorly compared to the 137 amino-acid 7B2A1 (Fig. 2B; com- 
pare lanes 6 and 7 with 8-9). These results imply that processing 
at the Lys138-Lys 139 residue of human 7B2 may be potentially 
suited for secretion in yeast. If this happened naturally, one 
would expect hat molecules similar to 7B2A 1 would be sponta- 
neously secreted from yeast. This event would not be so un- 
likely as there is precedence for similar processing at an identi- 
cal site in the vertebrate X. laevis [5]. 
It can be argued that by providing for a Lys138-Arg 139 residue, 
instead of the tys138-tys 139 sequence already existing in the wild 
type protein, it might be possible to make 7B2 more amenable 
to processing by the yeast KEX2 gene product [21]. The KEX2 
gene encodes an endopeptidase which plays an active part in 
the proteolytic processing of precursors of the ct-factor phero- 
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Fig. 3. Human 7B2, when expressed ina Kex2- strain of yeast, secretes 
molecules similar in size to 7B2A1. Proteins from cell supernatants and 
lysates were analyzed by Western blotting, as described in Fig. 2. (I) 10 
~tl supernatant (concentrated 20-fold) was loaded in each lane, except- 
ing lane 8 where a 5-fold concentrated supernatant was used. Lane 1, 
200 ng recombinant 7B2 protein (as in Fig. 2); lane 2, yHB13a (Invss- 
7B2_K 139R in AB 110); lane 3, yHB5b (Invss-7B2 in AB 110kex2); lanes 
4 and 5, yHB13b (Invss-7B2_K139R in ABllOkex2); lanes 6 and 7, 
yHB14 (Invss-7B2_K139R/sKex2pHDEL in ABllOkex2); lane 8, 
yHB6a (Invss-7B2A1 in ABll0); lane 9, yHB6b (Invss-7B2A1 in 
AB1 lOkex2). (II) 4/tl cell lysate was loaded in each lane. Lane 1,200 
ng recombinant 7B2 protein; lane 2, yHBl3a; lane 3, yHB5b; lane 4, 
yHB6a; lane 5, yHB6b; lanes 6 and 7, yHB13b; lanes 8 and 9, yHBI4. 
The protein markers used were the same as in Fig. 2. 
mone and killer toxin [22]. The Kex2 protein is a unique cal- 
cium-dependent serine-protease which has substrate specificity 
toward the carboxyl side of Lys-Arg, Arg-Arg and Pro-Arg 
sequences [23]. 
Surprisingly, secretion is not observed on expressing 
7B2_K139R (which contains the tys  139 to Arg mutation) in the 
yeast strain AB110 (Fig. 3A, lane 2). It appears as if the newly 
introduced Lys138-Arg ~39 substrate in 7B2 is not recognized by 
Kex2 so as to permit cleavage of the molecule. Could it be that 
Kex2-recognition is facilitated if cleavage was attempted during 
folding of 7B2? There is a possibility that the Lys138-Arg139 
motif would remain exposed before the polypeptide wholly 
acquires its native conformation. Since folding of secretory 
proteins is believed to occur in the ER [24], we endeavoured to
use an ER-retained variant of KEX2 (i.e. sKEX2HDEL) [18] in 
a strain where the KEX2 gene was inactivated by targeted 
gene-disruption [18]. The results show that the action of the 
sKex2pHDEL protein on 7B2 may be of marginal help to the 
secretion of 7B2Al-like molecules (Fig. 3A, lanes 6 and 7). 
Amazingly however, the secretion of 7B2 occurs most effi- 
ciently when any form of Kex2 is totally absent from the cell 
(Fig. 3A, lanes 4 and 5), indicating that sKex2pHDEL may not 
have a real role in the secretion of 7B2. In the Kex2- strain 
ABllOkex2, full-length 7B2 clearly secretes as a 7B2Al-like 
molecule (Fig. 3A, lane 8). Although replacement of Lys by an 
Arg is perceptibly beneficial (Fig. 3A, compare lane 3 with lanes 
4 and 5), secretion can be still perceived (Fig. 3A, lane 3) even 
if the residue at position 139 were Lys (as in the wild type 
human 7B2). These findings are reminiscent of the processing 
of pro-a-factor in a Kex2- strain [11] and suggest that an alter- 
nate endoprotease, probably Yap3, might function in the proc- 
essing of the precursor 7B2 allowing secretion of a truncated 
molecule. Apparently, Yap3 is induced in Kex2- strains when 
pro-a-factor is overexpressed from a multi-copy plasmid [11], 
signifying that Yap3 induction is triggered when multiple copies 
of its substrate are expressed in strains which lack a functional 
KEX2 gene. 
In order to find out if Yap3 really does play a part in the 
processing of precursor 7B2 in yeast, the YAP3 gene [11] was 
co-expressed with 7B2 from a 2/l-plasmid (pHBI 7). The levels 
of 7B2 secretion are appreciably more in strains which overex- 
press Yap3 (Fig. 4, lanes 5-8) than in strains which have only 
the genomic opy (Fig. 4, lanes 3 and 4). It was also reassuring 
that amounts of secreted 7B2A1 are similar in the strains AB110 
and AB1 lOkex2 (Fig. 4, lanes 5 and 6, and 7 and 8), implying 
that the Yap3 and Kex2 enzymes may not have conflicting roles 
during the secretion of 7B2. 
Studies with purified Yap3 have shown that it can cleave at 
both Lys-Lys and Lys-Arg residues [10]. Moreover, it has been 
proposed that Yap3 can cleave certain polypeptides atmonoba- 
sic Arg residues [25-26]. The yeast aspartic protease Yap3 has 
been found to be functionally identical to the mammalian as- 
partic protease, POMC converting enzyme [10]. Interestingly, 
the secretion of POMC- and 7B2-derived peptides is probably 
intertwined and seems to occur in an extremely cooperative 
manner in X. laevis [5], where inhibition of secretion of POMC- 
derived molecules also prevents ecretion of 7B2 derivatives. 
Therefore, it is likely that two similar enzymes (which could be 
even identical) process 7B2 and POMC before allowing secre- 
tion of their cleavage products. 
In spite of the implied role of Yap3 in the secretion of 7B2, 
it was still difficult to understand that wild type Kex2 should 
fail to perform its normal function when co-expressed with 7B2. 
In order to investigate if Kex2 could be inactive in strains 
co-expressing 7B2, the fusion protein proaFL-IGF1 (proaFL 
represents the prosequence of pro-a-factor) [18, 27-28] was 
used as an in vivo substrate. We have shown earlier that, using 
this substrate, activity of Kex2 can be measured by the release 
of human insulin-like growth factor-1 ( IGFI)  into the extracel- 
lular medium [27]. It ought to be remembered that, in a Kex2- 
strain (AB1 lOkex2), proaFL-IGF1 is not processed and ma- 
ture IGF1 remains undetected in the cell supernatant, whereas 
in a Kex2 ÷ strain (ABll0) mature IGF1 is formed although 
some preproaFL- IGF 1 (Fig. 5, bands marked with an asterisk) 
is also observed (presumably because the IGFI  precursor fails 
to undergo complete translocation i to the ER) [28]. Analysis 
of intracellular proteins from AB 110kex2 show that the precur- 
(!) kDa 
19=~ 
19=D 
Fig. 4. 7B2 secretes as a truncated 7B2Al-like molecule when Yap3 [11] 
is overexpressed in AB110 and AB1 lOkex2. Proteins were analyzed by 
Western blotting, as in Fig. 2. (I) 10/ll supernatant (concentrated 
20-fold) was loaded in each lane. Lane 1, 200 ng recombinant 7B2 
protein (as in Fig. 2); lane 2, yHB13a (Invss-7B2_K139R in ABll0); 
lanes 3 and 4, yHB13b (Invss-7B2_K139R inAB1 lOkex2); lanes 5 and 
6, yHB17a (Invss-7B2/Yap3 in AB110); lanes 7 and 8, yHB17b (Invss- 
7B2/Yap3 in AB1 lOkex2); lane 9, yHB6a (Invss-7B2A1 inAB110). (II) 
4/~1 cell lysate was loaded in each lane. Lane 1, yHB5a (Invss-7B2 in 
ABll0, as a control); lane 2, yHB6a; lane 3, yHBl3a; lanes 4 and 5, 
yHB13b; lanes 6 and 7, yHB17a; lanes 8 and 9, yHBl7b. The protein 
markers used were the same as in Fig. 2. 
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Fig. 5. Kex2 is unable to process the pro~FL-IGF1 fusion protein when 7B2 is present in the yeast cell. All proteins were analyzed by Western blotting 
using the IGF1 polyclonal antibody, as in Fig. 2. The total proteins in the cells (obtained after lysis in 0.1 M sodium phosphate, pH 7) were roughly 
the same (280-300/2g/ml, using the Bradford protein-assay kit from Bio-Rad). Treatment of cell lysates with endoglycosidase F was performed 
following published procedures. (I) Lane 1, purified 100 ng IGF1 monomer [17]; lane 2, yBCla (~FL-IGF1 in AB110) [28]; lanes 3 and 4, yBClb 
(~FL-IGF1 in AB1 lOkex2); lanes 5 and 6, yHB16 (Invss-7B2A1 and ~FL-IGFI in AB110); lanes 7 and 8, yHB15 (Invss-7B2 and ~FL-IGF1 in AB110). 
(II) Samples after deglycosylation with endoglycosidase F [18]. Lane 1, 100 ng IGF1 monomer; lane 2, yHB16 (+endo F); lane 3, yBClb (+endo 
F); lane 4, yHB15 (+endo F); lane 5, unglycosylated pro~FL-IGFI (as control) [28]. The bands marked with an asterisk (*) represent prepro~FL- 
IGF1. The protein markers were the same as in Fig. 2. 
sor pro~FL-IGF1 is highly glycosylated (visible as diffuse 
bands on polyacrylamide g ls; see Fig. 5A, lanes 3 and 4), which 
is typical of proteins that have traversed through the Golgi 
cisternae without being processed by the Kex2 enzyme [18, 
27-28]. In marked contrast, the glycosylated intermediate 
pro~FL- IGFI  is barely visible in AB l l0  (Fig. 5A, lane 2) be- 
cause most of the molecules have undergone processing by the 
Golgi-resident Kex2 (cleavage occurring at a Lys-Arg residue 
which links pro~FL to |GFI) .  
We find that co-expression of 7B2 and Kex2 drastically re- 
duces the release of mature IGFI  into the medium (results not 
shown). An immune-blot of intracellular proteins depicts that 
Kex2 in the strain yHB5a (see Table 2) is nearly as inactive as 
the non-functional copy of Kex2 in the strain AB1 lOkex2 (Fig. 
5A, compare lanes 3 and 4 with 7 and 8). Most of the heteroge- 
neous mix of glycosylated pro~FL-IGF1 molecules from 
yHBI5 can be deglycosylated by treatment with endoglycosi- 
dase F (Fig. 5B, compare lanes 3 with 4). Significantly, co- 
expression of the truncated 7B2A1 protein does not have a 
palpable effect on the processing of pro~FL- IGFI  (Fig. 5A, 
lanes 5 and 6). This emphasizes that Kex2 is functional in the 
presence of 7B2AI and underlines the efficacy of the 48 amino- 
acid C-terminal region of human 7B2 in inhibiting Kex2. It is, 
therefore, likely that binding of this domain to Kex2 prevents 
secretion of the complete 7B2 molecule from yeast. 
The inference that 7B2 has the capacity to inhibit Kex2 subtly 
reflects earlier findings involving the human 7B2 protein [7]. In 
vitro experiments have shown that complete 7B2, and not a 
molecule similar to 7B2A2, inhibits the prohormone convertase 
PC2 [7]. The action on PC2 is very specific since a related 
enzyme PCI/PC2 appears to be unaffected by 7B2. Altogether, 
six mammalian processing enzymes (the prohormone conver- 
tases furin/PACE, PC1/PC3, PC2, PACE4, PC4 and PC5/PC6) 
have been discovered to exhibit significant similarities in pri- 
mary sequence to Kex2, the yeast enzyme related to the bacte- 
rial subtilisins [3]. Therefore, it is not a mere coincidence that 
the C-terminal domain of 7B2 is meant o inhibit yeast's only 
Kex2 protease, the prototype of the eukaryotic family of pro- 
hormone convertases. 
We believe that the results reported in this communication 
could facilitate the understanding of the molecular basis for 
inhibition of a specific class of serine proteases (i.e. the pro- 
hormone convertases). Moreover, the observation that 7B2 is 
processed by an aspartic protease should provide further in- 
sight into the anomalous ecretion of 7B2 from a variety of 
neuroendocrine tumors. It has been suggested that the protein 
could be used as an efficient diagnostic marker for these tumors 
since they secrete 7B2 in very high amounts. [29-30]. If aberrant 
secretion of 7B2 is mediated by the action of a Yap3-1ike con- 
vertase, it is possible that inhibition of such an enzyme could 
deprive certain tumor cells of its tumorogenic potential. Hence, 
the yeast S. cerevisiae also furnishes an excellent opportunity 
to identify the processing enzymes involved in the biogenesis 
of the secreted form of 7B2. 
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